rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DTIL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Precision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B - Slideshow

      2026-11-13. The following slide deck was published by Precision BioSciences, Inc.

      Nov 13Seeking AlphaDTIL
      PDS Biotechnology: Q3 Earnings Snapshot
      Nov 13Yahoo FinanceDTILPDSB
      Precision BioSciences prices 10.24M shares at $7.75 in underwritten offering
      Nov 5Yahoo FinanceDTIL
      Precision BioSciences prices $125M stock offering at $7.75
      Nov 5Investing.comDTIL
      Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
      Nov 5Yahoo FinanceDTIL
      Precision BioSciences earnings beat by $0.56, revenue fell short of estimates
      Nov 3Investing.comDTIL
      Precision BioSciences: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceDTIL
      Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 3Yahoo FinanceDTIL
      Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026

      DURHAM, N.C., October 29, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2026 and provide a business update on Tuesday, November 3, 2026.

      Oct 29Yahoo FinanceDTIL
      Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

      DURHAM, N.C., October 08, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77th annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2026 will take place November 5-9 in Denv

      Oct 8Yahoo FinanceDTIL
      Precision Biosciences director Geno Germano buys $16,384 in stock
      Sep 29Investing.comDTIL
      Precision Biosciences director Melinda Brown buys $7,116 in stock
      Sep 29Investing.comDTIL
      Precision BioSciences at H.C. Wainwright conference: two shots on goal
      Sep 17Investing.comDTIL
      Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera
      Sep 12BarchartDTILIONS
      Precision BioSciences doses first patient in DMD gene editing trial
      Aug 24Investing.comDTIL
      Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

      DURHAM, N.C., August 24, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

      Aug 24Yahoo FinanceDTIL

      This is the newest page. Registered accounts read further back.